The study, which appears in the journal Pharmaceutical Research, investigated a new kind of antitumor chemical called RCn. When evaluated for its ability to kill cancer cells in mice, hospital researchers found RCn was more than 10 times more effective in eliminating tumor cells than regular cells, meaning the low dose necessary to impact cancerous cells will have minimal effect on normal cells, according to the researchers.
“This is particularly important for proving the safety of a potential therapy,” Timothy Cripe, MD, principal investigator on the research, said in a statement. The study authors are working to further test the capabilities of the new drug.
More articles on quality:
Regional differences in cancer treatment vary widely across Texas
Researchers create cancer-fighting bacteria
Providers don’t understand CT scan cancer risk, study suggests
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
